Johnson & Johnson news

   Watch this stock
Showing stories 1 - 10 of about 248   

Articles published

JNJ 133.15 +1.92 (1.46%)
price chart
Theravance Biopharma: Johnson & Johnson Deal Looks Solid
The deal with JNJ adds even more credibility to the story, and economics of the pact are generous. The stock could represent an ideal choice for readers who shy away from one-product companies and stocks with high amounts of binary risk.
Berko: Johnson & Johnson and talcum powder
Now I read that Johnson & Johnson is in serious trouble because its talcum powder, which I began using 40 years ago after showers, may cause cancer.
Why I Recently Bought Johnson & Johnson
Johnson & Johnson (JNJ) has been one of the most respected, well-managed, and consistent companies for decades now. When thinking of dividend growth staples, one of the first companies that come to mind for most investors is JNJ.
Johnson & Johnson (JNJ): From Top to Bottom  StockNewsJournal
Johnson & Johnson (JNJ) Stock Rating Reaffirmed by BTIG Research  StockNewsTimes
Johnson & Johnson falls on report that lawsuits could expose potentially ...
Johnson & Johnson falls on report that lawsuits could expose potentially damaging documents. Johnson & Johnson's stock fell on a report that court proceedings could expose potentially damaging documents. J&J is facing numerous lawsuits claiming its ...
Johnson & Johnson falls on report that lawsuits could expose damaging ...  ABC10
Johnson & Johnson Mesothelioma Trial Likely to Expose Company Documents  Mesothelioma.net Blog (blog)
Johnson & Johnson's stay-out-of-jail marketing for schizophrenia blockbuster ...
Just after New Year's, in an announcement that was easy to overlook in the post-holiday haze, Johnson & Johnson's Janssen Pharmaceutical celebrated an historic FDA approval. The agency cleared new label language for the company's 9-year-old ...
Johnson & Johnson falls on 'disappointing' sales outlook
Shares of Johnson & Johnson turned negative as investors reacted to a lackluster sales growth outlook. The company topped Wall Street's fourth-quarter earnings and revenue expectations with boosts from new cancer drugs and its acquisition of Swiss ...
Johnson & Johnson and talcum powder. What's next? — Malcolm Berko
Now I read that Johnson & Johnson is in serious trouble because its talcum powder, which I began using 40 years ago after showers, may cause cancer.
The case for Johnson & Johnson
Johnson & Johnson isn't just a big pharma; it's a big consumer healthcare and big medical device company, too. These other two business segments have generated only modest growth for the healthcare giant recently, though.
Better Buy: Eli Lilly and Company vs. Johnson & Johnson  Madison.com
Johnson & Johnson's Tremfya shows sustained treatment effect in late-stage ...
New data from a Phase 3 clinical trial, VOYAGE 2, evaluating Johnson & Johnson (JNJ +0.9%) unit Janssen Pharmaceuticals' TREMFYA (guselkumab) in patients with moderate-to-severe plaque psoriasis showed a durable treatment effect.
Johnson & Johnson Sees First Investor Suit Over Talc-Cancer Link
Similar allegations regarding asbestos “were soundly rejected by a California jury in November 2017,” he told Bloomberg Law in an email.